In the era of personalized medicine as well as precision medicine, targeted therapy has become an integral part of cancer treatment in conjunction with conventional chemo-and radiotherapy. We designed aptamer-siRNA chimeras that can specifically target cancers expressing EpCAM, a stem cell marker and deliver the specific siRNA required for therapy response. The siRNAs were chosen against PLK1, BCL2 and STAT3 as these oncogenes play prominent role in tumour progression of several cancers. Targeted delivery of EpCAM-siRNA chimeras resulted in cell death in several cancer cell lines such as cancers of the breast, lung, head and neck, liver and retinoblastoma. In vivo analysis of EpCAM-siRNA chimera mediated silencing on RB xenografts tumour model showed increased tumor reduction in all the three EpCAM-siRNA treated conditions. However, regulation of PLK1 exhibited higher efficacy in tumour reduction. Therefore. We studied signaling mechanism using global phosphoproteomics analysis. An increased P53 mediated downstream signalling pathway might have enabled increased apoptosis in the cancer cells. In conclusion, this study demonstrated the efficacy of EpCAM aptamer chimeras coupled to siRNA gene silencing for targeted anti-cancer therapy.
INTRODUCTION
Limitations of conventional chemotherapeutic drugs due to non-specificity present a major challenge for cancer therapy. These shortcomings are largely attributed to the ability of cancer cells to repopulate and metastasize after initial therapies which makes them resistant to chemotherapy and radiotherapy. Thus there is a need to eliminate the cancer cells by specifically targeting the mechanisms which promote the cells survival and progression. The most common method to hamper the cell cycle progression is by blocking the activity of selected genes using a siRNA. Short interfering RNAs (siRNAs) are oligonucleotide-based pharmaceuticals with a promising role in targeted cancer therapies 1 . These have great therapeutic potential and specificity, but their shortcomings remains the delivery and internalisation into cells and off-target effects. Though lipid based delivery of siRNA is routinely used, its efficiency is hampered due to its in vivo instability and lack of target tissue delivery. Numerous strategies are underway to eliminate cancer cells specifically by targeting surface biomarkers coupled with regulation of oncogenes and application of novel delivery technology to combat cancer. Hence, drug delivery systems using aptamer technology are used to enhance the specific delivery of these siRNAs to the targeted sites 2 . Aptamers are short RNA/DNA molecules that specifically bind to target proteins with high affinity 3, 4 .Various forms of aptamer-chimeras, (aptamers conjugated with drugs and biomolecules like siRNAs) have been extensively applied in many cancer therapeutics 5 . These aptamers not only bind to specific cancer cells but are also internalized by the process of receptor mediated endocytosis and deliver the respective biomolecule attached to it 6 . Aptamer-siRNA chimeras have been found to be proficient in inhibiting tumour progression 7 . Various targeting aptamers have been reported till now, which include prostrate specific membrane antigen (PSMA) 7 , B cell activating factor receptor (BAFF-R) 8 and Epithelial Cell Adhesion Molecule (EpCAM) 6 .
These targets are mainly chosen depending on their exclusive expression on the specific cancer cell type.
EpCAM is a well-established cancer stem cell marker identified in many tumours. A nuclease-resistant aptamer targeting EpCAM was found to be clinically beneficial for both diagnostics and therapeutics 9 .
EpCAM aptamer chimera conjugated with PLK1 siRNA was also found effective in restricting tumour growth in breast cancer 10 . However studies are lacking on the efficacy of these EpCAM aptamer chimeras in reducing tumour growth in other cancer models. Hence, targeting various cancer cells using EpCAM aptamer-siRNA chimera against oncogenes that are overexpressed in several solid tumours would be an effective anticancer therapeutic in combating different cancers.
Many anticancer drugs have been developed targeting oncogenes due to their ability to suppress cell death such as Polo-like Kinase 1 (PLK1), B-cell Lymphoma 2 (BCL2) and Signal transducer and activator of transcription 3 (STAT3) 11, 12 . PLK 1 is a critical oncogene that is involved in centrosome maturation in the late G2/early stages of cell cycle progression 13 and activation of Cdc25 14 , thereby leading to uncontrolled cell division and cancer progression. While PLK1 contributes to cancer by inducing uncontrolled cell progression, BCL2 acts as anti-apoptotic marker by preventing cell death 15 .
Overexpression of BCL2 has been seen in many cancers especially in invasive tumours and is known to play a major role in the survival of the cell 16, 17 . An aberrant STAT3 signalling promotes initiation and progression of many cancers either by inhibiting apoptosis or by inducing cell proliferation 18 . Furthermore, consistent overexpression of STAT3 was observed in angiogenesis, cellular invasion and survival 19 .Thus targeting these oncogenes and blocking their expression would inhibit cell proliferation and result in reduced tumour growth. In our previous study we have shown that EpCAM aptamer-siPLK1 chimera identified a novel prominent role of lipid synthesis for the oncogene PLK1 20 . However, extensive investigations on reducing tumour burden and signalling mechanism leading to cancer cell death was not studied.
Additionally, efficacy of EpCAM aptamer mediated regulation of BCL2 and STAT3 are not reported before.
Hence, we designed and studied the EpCAM aptamer chimeras with siRNA for PLK1 (EpCAM-siPLK1), BCL2 (EpCAM-siBCL2) and STAT3 (EpCAM-siSTAT3) in several cancers which overexpress EpCAM.
The in vitro cell line model that exhibited superior efficacy was further tested in mouse xenograft model. The molecular signalling mechanism was studied for the best performing aptamer-siRNA chimera using SILAC-based phosphoproteomics analysis.
RESULTS
We targeted various cancer cells specifically by using an already available EpCAM binding RNA aptamer.
This served as a carrier molecule to deliver the siRNAs (siPLK1, siBCL2, siSTAT3) to EpCAM expressing cancer cells.
Designing of EpCAM-siRNA chimeras
EpCAM aptamer chimeras were designed using bioinformatics approaches. The silencing activity and specificity of these aptamer-siRNA chimeras were enhanced by incorporating few modifications like adding 2-nucleotide, 3'-overhangs to increase its stability against endogenous cell nucleases and including a dicer recognition site. The aptamers were designed having the sense strand of the siRNA starting at the 5' end of 20 nt length followed by the truncated EpCAM aptamer sequence of 20 nt and then the antisense strand having 20 nt with a 2 nt (UU) overhang a the 3' end. This design increases the stability of the chimera and makes it easy for the dicer enzyme to cleave the chimera at the 21 st nucleotide and release the siRNA from the EpCAM aptamer ( Figure 1A) . The EpCAM aptamer sequence is in the middle of the sense and antisense strand in each EpCAM-siRNA chimera. The 3' end of the chimera is fluorescently labelled with FITC. The designed aptamer was cleavable by dicer enzyme in vitro into EpCAM aptamer and the respective siRNA ( Figure 1B ).
Expression of EpCAM in different cancer cell lines
Several cancer cells such as breast, pancreatic, lung cancer, head and neck and Retinoblastoma (RB) were examined for the expression of EpCAM using PCR and quantified using qPCR ( 
Binding and internalisation of the chimeras in EpCAM expressing cell lines
The binding and internalisation of the EpCAM chimeras in various epithelial cell lines were compared in those cell lines which showed higher amount of EpCAM expression. These chimeras were designed specifically to bind to EpCAM + cells and deliver the siRNA. Since the aptamers are FITC labelled, its binding efficacy in EpCAM expressing cell lines was examined by flow cytometry (Figure 3A ) and fluorescence microscopy (Figure S1). As shown in Figure 3A , the fluorescence intensity from the chimeras bound to NCC RbC 51 and MCF-7 was higher than those bound to HepG2 and RPMI 2650. However, all cell lines exhibited greater binding efficiency compared to the control cell line Mio M1 which showed very minimal binding (10%) even at a very high concentration (1000nM) of the chimera. About 90% of binding was achieved in NCC RbC 51 with a minimum concentration of 100nM EpCAM-siRNA. In MCF-7 cells, as the concentration of the chimera increased, a gradual increase in binding was seen. 85% binding was seen with 300 nM aptamer concentration. However, further increase in the concentration resulted in saturation of binding to MCF7 cells. Whereas, in RPMI 2650 and HepG2 cells only 50-60% binding of EpCAM-siRNA was observed even at a very high concentration of 500nM. These results indicate that the binding of the chimeras to the cancer cells may be proportional to the magnitude of EpCAM expression in these cells.
Furthermore, higher expression of EpCAM on MCF-7 and NCC-RBC 51 might have enabled higher aptamer chimera binding on these cells.
EpCAM-siRNA mediates dose dependent cytotoxicity
To assess the cytotoxic effect of EpCAM-siPLK1, EpCAM-siSTAT3 and EpCAM-siBCL2, a panel of cancer cell lines and control cell line were exposed to the chimeras for 72 h at varying concentrations ranging from 100-500 nM and cell viability was assessed using MTT assay ( Figure 3B) . A very minimal cytotoxicity was seen in the control cell line Mio M1 after treatment with all the three chimeras. These aptamer chimeras could not bind to the Mio M1 cells ( Figure 3B ), resulting in lack of cell death in these cells. In RPMI 2650 and HepG2 significant (p value < 0.05) cell death was observed only at higher concentrations of Ep-siPLK1 and Ep-siSTAT3 (500nM). This is in agreement with the EpCAM expression 
EpCAM aptamer mediated cell type specific knockdown of target genes
Next we studied the ability of the aptamer chimeras to silence the expression of the chosen oncogenes specifically in EpCAM + cancer cells. The chimera once specifically bound to EpCAM positive cells, can internalise and deliver the respective siRNA tagged to it, which binds to the target gene and silence its expression. The three siRNAs used in our study are specific to important oncogenes which, when silenced can result in inducing apoptosis and eventually causing cell death. The minimal concentration of the chimeras which showed maximum cytotoxic effect for the specific cell line were chosen for further analysis A concentration of100 nM was used for MCF-7 &NCC RbC 51 wheras 500 nM was used for HepG2 and RPMI 2650. The reduction in PLK1, STAT3 and BCL2 gene expression on treatment with the EpCAM-siRNA chimeras were compared to siRNA alone to investigate the targeted ability of these aptamers in EpCAM + cancer cells. In the EpCAM ▬ cell line Mio M1, the knockdown of PLK1, BCL2 and STAT3 were observed in siRNA treated cells alone and not in the aptamer chimera treated cells. In RPMI 2650 and HepG2 cells, the downregulation of the oncogenes was higher in siRNA treated cells compared to their aptamer chimera treated cells (Figure 4A) . The partial knockdown in the oncogenes observed in HepG2 and RPMI 2650 could be due to moderate binding of the aptamer chimeras regulated through the EpCAM expression in these cells. Whereas in MCF-7 and NCC RbC 51 the downregulation of PLK1, BCL2 and The knockdown of PLK1, STAT3 and BCL2 at protein level was checked in NCC RbC 51 cells after treatment with the aptamer chimera. The downregulation of PLK1 and STAT3 were found to be more in EpCAM-siRNA chimera treated cells compared to siRNA treated cells ( Figure 4B) . The siRNA was more effectively delivered by EpCAM aptamer than lipofectamine, which shows that this could be a potential targeted delivery system for EpCAM positive cancers. However, magnitude of BCL2 protein reduction was lowest even though the binding of the chimera to the cancer cells was same as other two chimeras. The EpCAM-siScr chimera did not reduce oncoprotein expression. Therefore, these results show that the EpCAM-siRNA, but not EpCAM-siScr, is able to deliver the siRNA and regulate the gene/protein expression in a cell type specific manner.
EpCAM-siRNA induced apoptosis in NCC RbC 51 cell line
To confirm the occurrence of apoptosis on treatment with EpCAM-siPLK1, EpCAM-siSTAT3 and EpCAM-siBCL2 in NCC RbC 51, Annexin-PI staining was performed and analysed using flow cytometry after 48 h treatment with EpCAM-siPLK1 ( Figure 4C ). There was an increase in early apoptotic cell population (Annexin V+ PI -) from 0.34% to 39.00% and an increase in late apoptosis (Annexin V+ PI + ) from 0.12% to 47.02%. We did not observe any necrotic population. EpCAM-siSTAT3 treatment, resulted in an increase in the early apoptotic cell population (Annexin V+ PI -) from 0.47% to 15.99% and an increase in late apoptosis (Annexin V+ PI + ) from 0.22% to 22.35%. Additionally, the cells in the process of necrosis increased from 1.12% to 19.6%. However, consistent with lower functional activity of EpCAM-siBCL2, reduced cell death through apoptosis was observed in NCC RbC 51 cells ( Figure 4C ).
About 88.38% of cells were found to be live, whereas 1.41% in early apoptotic, 2.49% in late apoptotic stage. However, 5.91% cells were observed in necrotic stage. The shift of the cells towards apoptotic stage indicates that the treatment with EpCAM-siRNA aptamers supresses the proliferation of NCC RbC 51 cells after the regulation of oncogenes by aptamer chimeras in this cell line.
Reduction of tumour burden through systemic administration of EpCAM-siRNA chimeras in the mouse xenografts model of RB
To assess the effect of the EpCAM-siRNA chimeras on tumour growth invivo, NCC RbC 51cells were injected subcutaneously in the right flank of the animal and tumour xenografts were established in athymic Nude-Foxn1nu male mice. Once the tumour attained a palpable size, animals were randomized based on tumour volume (TV ≈ 200 mm 3 ) and dosing was initiated. EpCAM-siRNA (100 μl, 0.8 nmol per mouse) was injected intraperitoneally to tumour bearing mice every third day for 30 days (10 cycles).
A significant tumour reduction (p<0.05) was seen in EpCAM-siPLK1 and EpCAM-siSTAT3 treated mice when compared to the control (Figures 5A and B) . Howerver, a greater percentage of tumour reduction (56.11%) was seen in EpCAM-siPLK1 treated mice compared to aptamer chimeras after 10 cycles of treatment in a span of 30 days. The tumour size was nearly 1600mm 3 in control and reduced to 834 mm 3 in EpCAM-siPLK1 and 988 mm 3 in EpCAM-siSTAT3 chimeras treated mice, respectively. However, when treated with EpCAM-siBCL2, the average tumour size was found to be 1250 mm 3 showing a reduction of only 34.21% compared to vehicular control mice. Upon treatment with EpCAM-siBCL2, a significant (p<0.05) reduction was observed in 3 animals, whereas, 2 animals were found to be non-responders indicating reduced ability of this chimera to arrest tumour growth compared to other two chimeras.
However, all the three aptamer chimeras were non-toxic to the animals. Furthermore, the body weight of the animals was also found to increase in a definite manner in both treated and untreated conditions till the end of the study (Figure 5C) . Additionally, the aptamer chimera treatments did not cause any structural changes in the detoxifying organs such as liver and kidney ( Figure S2 ).
Assessment of Anti-proliferative effect of EpCAM-siRNA chimeras
To assess the anti-proliferative effect of the chimeras on the xenografts, immunohistological analysis for cell proliferation markers Ki67, p53 and anti-proliferative marker BCL2 was performed. H&E staining revealed lot of dead cells in EpCAM-siRNA treated conditions. Ki67, a nuclear specific marker for cell proliferation, was highly expressed in control mice compared to all the aptamer chimera treated tumour tissues (Figure 6) .
The decrease in Ki67 reactivity indicates decreased cancer cell proliferation after aptamer chimera treatments, suggesting the anti-proliferative role of the EpCAM-siRNA chimeras. We then tested for the anti-proliferative and anti-apoptotic markers, p53and BCL2, respectively, to understand if the tumour cell death is mediated through apoptosis as all the three silenced genes in the present study are found in p53 signalling pathway. After the administration of the aptamer chimeras, p53 protein expression increased and BCL2 protein expression decreased in EpCAM-siPLK1 & EpCAM-siSTAT3 treated mice compared to the control. For studying the proliferation after the EpCAM-BCL2 aptamer chimera treatment, the tumour tissue from the respondent mice was used for studying Ki67, P53 and BCL2 protein expression. In these tumours Ki67 and BCL2 protein expressions decreased with concomitant increase in P53. However nonresponders had no upregulation of P53 (data not presented). The switching of proliferation of the tumour cells into apoptosis was brought after the aptamer chimera treatments. This ensures that the cells are undergoing apoptosis when a particular oncogene (PLK1, BCL2, STAT3) was silenced, resulting in the suppression of tumour growth.
Phosphoproteomics identified altered signalling proteins
We observed that EpCAM-siPLK1 chimera exhibited higher therapeutic efficacy compared to the other two chimeras in both in vitro and in vivo models (Figures 3b and 5 ). PLK1, a kinase, plays a major role in phosphorylating many oncoproteins. Silencing PLK1 would certainly have an impact on the phosphorylation status of its downstream targets. Hence we chose to study the altered signalling pathways upon silencing PLK1 by Stable Isotope Labelling with Amino acids in Cell culture (SILAC) -based phosphoproteomics analysis. We identified about 3501 phosphopeptides PLK1-dependent phosphorylation sites which mapped to 1493 proteins (Supplementary data 1) . We considered 1.5-fold change in phosphorylation status of identified peptides for analysing differential expression of proteins when PLK1 is down regulated.
A set of 904 peptides were hypophosphorylated and 1382 were hyperphosphorylated after the EpCAM-siPLK1 aptamer chimera treatment, which corresponded to 552 hypophosphorylated and 798 hyperphosphorylated proteins. Partial list of hypophosphorylated and hyperphosphorylated proteins and the corresponding pathways are given in Table 1 . Interestingly, p53 phosphorylation was identified in our global phosphoproteomic analysis (Supplementary data 1) and increased p53 protein expression was seen in EpCAM-siPLK1 treated mouse tumours ( Figure   6 ). Therefore, we examined several phosphorylated proteins that are related to P53 signalling pathways. 14-3-3 proteins which regulate cell cycle were found to be downregulated (Supplementary data 1) .
Additionally, the expressions of cell cycle regulators like Chk1, cdc25, p53 and cdk1 were altered after the PLK1 knockdown. Major proteins which are known to be responsible for p53 phosphorylation were also identified in the study. We found that DNA-PK, p300, CBP, GS3Kβ, IKK and APC/C as hyperphosphorylated whereas GTSE1 was hypophosphorylated after the silencing PLK1 stating the reason for enhanced levels of p53. We also found proteins involved in the cell survival pathway (PKB/Akt, GSK3β, IKK and APC/C) to be regulated after PLK1 knockdown. Interestingly, dysregulation of phosphorylation was also observed in the proteins associated with the metabolic regulation of the cells, where S6 and EIF4E-BP1 was hypophosphorylated and hyperphosphorylated, respectively. Additionally, AMPK was hyperphosphorylated when PLK1 is down regulated.
DISCUSSION
Therapeutic application of aptamer-siRNA chimeras for treating cancer is a promising technique to deliver the siRNA to specific tumour cells and eliminate them completely while reducing the off target effects on the normal cells 21 . Presently, we designed aptamer chimeras to specifically target cancer cells by recognising overexpression of EpCAM and deliver the siRNA that regulate the oncogene expression in these cells. In consistence with the designed features, the reduction in the oncogene Additionally, in-vivo mouse xenograft model showed effective tumour reduction in nude mice on treatment with these chimeras. Several EpCAM conjugations like EpCAM-siRNA conjugations, EpCAM-drug and EpCAM-toxin conjugations have shown high efficacy in reducing cancer cell growth 21, 22 . Present study indicates that EpCAM mediated silencing of PLK1, STAT3 and BCL2 oncogenes can show targeted therapeutic ability to reduce tumours in mouse models.
The therapy response in mouse model could be due to the increased expression of p53 tumour suppresser protein and decreased anti-apoptosis protein BCL2. EpCAM-siPLK1 exhibited superior functional ability by greater tumour burden reduction compared to other two aptamers.
The signalling mechanism associated with superior therapeutic performance is further studied by global phosphoproteomics and mass-spectrometry. This technique is a valuable tool for identifying signalling after drug treatments in cancer models 23, 24 . The Bioinformatic analysis of deregulated phosphoproteins after PLK1 down regulation identified altered Map kinase, cell cycle and Wnt signalling pathways. The role of PLK1 in cell cycle progression through map kinase pathway is further strengthened using our global phosphoproteomic analysis in RB cells. The cross talk and integration of these two pathways leading to cancer is proposed in several cancers 25 . Similarly an alteration of Wnt signalling after the down regulation of PLK1 could also account for observed therapeutic effect in RB cells. An increased PLK1 expression modulated Wnt signalling pathway was identified in prostate cancer 26 .
On silencing PLK1, the increased levels in p53 and phosphorylation might also be a major reason for cell death via apoptosis. Over expression of PLK1 is known to phosphorylate GTSE1 and Topors which are direct substrates of p53 leading to inactivation of p53 27, 28 . EpCAM-siPLK1 mediated p53 accumulation in our study could be due to the hypophosphorylation of GTSE1. Furthermore, p53 is also a downstream target of DNA-PK which is regulated by PLK1 during mitosis 29 and the presence of DNA-PK results in the inactivation of Akt/PKB and activation of GSK3β, ultimately contributing to the accumulation of p53 30 . Alternatively, the increased p53 expression mediated by GSK3β have also been reported to result in Cyclin D1 expression leading to apoptosis 31 . Zhiguo Li showed that depletion of PLK1 inhibited the PI3K pathways 32 which coincide with our results where GS3Kβ, IKK, APC/C and p53 were hyperphorphorylated. Additionally, the increased phosphorylation seen in the tumour suppressor protein AMPK might be the strong reason for the metabolic shift in the functioning of the cells. The active form of PLK1 is known to be responsible for the phosphorylation of the downstream targets of AMPK such as S6 and 4E-BP1 through the mTOR pathway. Alternatively, p53 can also regulate the mTOR pathway through AMPK activation thereby increasing apoptosis in RB cells. Collectively, our phosphoproteomics analysis demonstrated that EpCAM-siRNA mediated knockdown of PLK1 eventually lead to alteration in cell cycle progression mediated through P53/ MAPK/Wnt signalling leading to apoptosis.
In conclusion, non-specificity of therapy in cancers is addressed using celltype specific aptamer chimeras which kills the cancer cells alone. The EpCAM aptamer chimeras could effectively reduce tumours in mouse xenograft models. This work also sheds light on the importance of PLK1 in cancer, and silencing the gene could lead to apoptosis at various cell cycle check points. The reduction in cancer growth could be due to the upregulation of p53/MAPKinase/Wnt mediated cellular signalling leading to increased cancer cell death. Our study paves a platform for efficient second line of therapies in addition to existing chemotherapy options for controlling cancer cell proliferation, reducing the off-target effects on normal cells.
MATERIALS AND METHODS

Reagents
For cell culture, RPMI 1640, DMEM, antibiotic-antimycotic solution, and FBS were purchased from Gibco Life Technologies, Waltham, MA, USA.
Aptamer design
Aptamer chimeras EpCAM-siPLK1, EpCAM-siSTAT3 and EpCAM-siBCL2 and EpCAM-siScr were designed. The lengths of the chimeras were designed to be 60 nucleotides containing a dicer recognition site between the EpCAM aptamer and the siRNA sequence. To increase the stability of the aptamer chimeras against endogenous nucleases, modifications like, adding 2 UU-nucleotide 3´ overhangs, optimizing the thermodynamic profile and structure of the duplex to favor the processing of siRNA guide strand, were made. The secondary structure prediction was done using RNA structure program version 5.0. The aptamer was fluorescently labelled with FITC at the 3' end to visualize binding of chimeras to the cells. The designed aptamer-chimeras were custom synthesized through Dharmacon, Lafayette, CO, USA.
Dicer cleavage assay
All EpCAM-siRNA chimera (100 nM) was denatured by heating for 10 min in a boiling water bath. 
Transfection
At about 85% confluency, the cells were treated with the above mentioned siRNA and EpCAM-siRNA chimeras. 100 nM of siRNA along with lipofectaminefor 24 h was used for transfection for all the cell lines.
In the case of EpCAM-siRNA chimeras different concentrations ranging from 100-500 nM was used depending on the cell line for 48 h.
Flow cytometry for binding efficacy
Approximately, 4×10 5 cells (Mio M1, NCC RbC 51, MCF-7, RPMI 2650, HepG2) were collected and washed twice with cold phosphate-buffered saline (PBS). Cells were then resuspended in blocking buffer (PBS with 0.02% sodium azide, 0.1% FBS, and 0.01% Triton X-100) and incubated with different concentrations (100 nM -500 nM) of FITC tagged aptamer chimeras (EpCAM-siPLK1, EpCAM-siSTAT3
and EpCAM-siBCL2). After 1 h, the cells were washed twice with ice cold PBS and resuspended in sheath fluid. About 1×10 4 cells were collected and analysed for binding efficacy of the chimeras using FACS (BD FACS Calibur system).
Flow Cytometry to check apoptosis using ANNEXIN/PI kit
Annexin/Propidium Iodide staining kit from BD Pharmingen, India (cat no:556547) was used to check the apoptotic levels. About 4×10 5 cells (Mio M1, NCC RbC 51, MCF-7, RPMI 2650, HepG2) were collected and washed twice with cold phosphate-buffered saline (PBS). Cells were then resuspended in 100 µl of 1X binding buffer present in the kit and incubated with 3 µl of Annexin and 2.5 ul of Propidium iodide.
Propidium iodide alone and Annexin alone stained samples were used for comparison. After 1 h, the cells were washed twice with 1X Binding buffer, resuspended in sheath fluid, and analysed for apoptotic effect of the chimeras using FACS (BD FACS Calibur system).
MTT assay
The 
Statistical analysis
For quantitative RT-PCR and western blotting experiments, data obtained from triplicates were analysed using Statistical Package for the Social Sciences (SPSS) software. The comparisons were performed using Student's t-test. P values less than 0.05 were considered as statistically significant.
NCC RbC 51 xenograft study
Culture of Tumour Cells
Xenograft studies were carried out at Biology Division, Syngene International, Bangalore, India. All procedures were performed in a laminar air flow hood following sterile techniques. Human NCC RbC 51, RB cells with a viability of >90 % was chosen for the study. Approximately 5 x 10 6 NCC RbC 51cells were re-suspended in 200 µL of serum-free media containing 50% of matrigel and kept on ice until cell injection.
Subcutaneous Injection of Cells
Male athymic nude mice (Hsd: Athymic Nude-Foxn1 nu ) housed in Individually Ventilated Cages (IVCs) were used for the present investigation. Cells were propagated in animals by injecting the cells subcutaneously in the right flank of the animals. The implanted area was monitored for tumour growth.
Once the tumour attained a palpable size, animals were randomized based on tumour volume (TV ≈ 200 mm 3 ) and dosing was initiated.
Formulation and Drug Dosage
Preparation of the test compound and dosing solutions
Required quantity of aptamers (Anti-PLK1, Anti-BCL2 and Anti-STAT3) were diluted in sterile water for injection to get final concentration of 8 nmol/ml as a working solution to deliver dose of 0.8 nmol/100µl/animal. Aliquots were prepared as per daily required doses and stored at -20⁰C. One tube from each test compound was thawed daily just prior to dose administration. The dose volume was maintained constant at 100 µL/animal. A single dose regimen was planned (Schedule -1: Q2D X 2 weeks-day 0, 2, 4, 6, 8, 10, 12 & 14) .
Xenograft mouse model
EpCAM-siPLK1, EpCAM-siSTAT3, EpCAM-siBCL2 was intraperitoneally injected into the mice every third day for 30 days and a total ten cycles were carried out. Tumour sizes and body weights were measured twice a week. The tumour volume was calculated according to the formula: TV(mm 3 ) = (L × W 2 )/2 (W, the width; L, length). The animals were euthanized two days after the last treatment. The tumours and organs were collected and fixed in 10% formalin buffer. The sections of tissues were analysed by H&E staining and immunohistochemistry.
Histology assay.
Animals were euthanized with CO 2 , and tumours were collected for all the four conditions. The vital organs (Liver, Kidney, lymph nodes, heart, lung, spleen and brain) were removed and fixed with 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.6). The serum was also collected separately.
Tissues were cut into 10 mm sections and were dehydrated in alcohol-xylene, and embedded in paraffin.
Sections were cut and mounted on to glass slides, deparaffinised in xylene and ethyl alcohol. Each block has a section for H&E staining. For immunohistochemistry assay, sections were incubated in 3% normal goat serum for 2 h and followed by overnight incubation with primary antibodies: Ki67, P53, BCL2, Cyclin DTT at 60 o C for 30 minutes and alkylated using IAA at room temperature for 10 minutes. Protein precipitation was done using 6 volume of ice cold acetone and digested overnight at 37 o C using modified trypsin (Promega). Then peptides were fractionated by bRPLC and 8 fractions were collected. TiO2-based phosphopeptide enrichment method was used to enrich the phosphopeptides from each fraction. Then enriched peptides were dried and cleaned using C18 stage tips.
LC-MS/MS analysis and data analysis
The peptides were analysed on a Thermo Scientific™Orbitrap Fusion™ Tribrid™ Mass Spectrometer (Thermo Scientific, Bremen, Germany) interfaced with Easy-nLC 1000II nanoflow The search parameters for both the algorithms included maximum of two missed cleavage, carbamidomethylation at cysteine and SILAC labels 13C6-Lysine; 13C6-Arginine as fixed modification.
Oxidation at methionine and phosphorylation at serine, threonine and tyrosine were set as dynamic modification. The data was searched against decoy database and false discovery rate was set ˂1% at PSM level. The probability of phosphorylation at S/T/Y site on each peptide was calculated using PhosphoRS node and peptides with more than 75% phosphoRS probability were considered to fetch the phospho site on protein level. The KEGG pathways were obtained using DAVID's functional annotation bioinformatics analysis. All MS data have been deposited in the PRIDE database with identifier PXD008221. 
